LivaNova’s latest VNS Therapy system has received CE mark for expanded MRI labelling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment.
The labelling change applies to the latest VNS Therapy technology, which includes AspireHC and AspireSR devices. Now, patients who have or desire to have VNS Therapy can more easily receive routine MRI scans.
To date, more than 100,000 patients worldwide use VNS Therapy—a minimally invasive treatment designed to prevent seizures before they start and stop them if they do.
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalisation) or generalised seizures that are refractory to seizure medications.
AspireSR (Seizure Response) features an Automatic Stimulation Mode which is intended for patients who experience cardiac rhythm increases that are associated with seizures.
